Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 241

1.

The propensity for epithelial-mesenchymal transitions is dictated by chromatin states in the cancer cell of origin.

La Belle AA, Schiemann WP.

Stem Cell Investig. 2017 May 26;4:44. doi: 10.21037/sci.2017.04.07. eCollection 2017. No abstract available.

2.

Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy.

Bressy C, Hastie E, Grdzelishvili VZ.

Mol Ther Oncolytics. 2017 Mar 21;5:20-40. doi: 10.1016/j.omto.2017.03.002. eCollection 2017 Jun 16. Review.

3.

Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.

Ferraiuolo M, Verduci L, Blandino G, Strano S.

Int J Mol Sci. 2017 May 3;18(5). pii: E961. doi: 10.3390/ijms18050961. Review.

4.

Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma.

Wittig-Blaich S, Wittig R, Schmidt S, Lyer S, Bewerunge-Hudler M, Gronert-Sum S, Strobel-Freidekind O, Müller C, List M, Jaskot A, Christiansen H, Hafner M, Schadendorf D, Block I, Mollenhauer J.

Oncotarget. 2017 Apr 4;8(14):23760-23774. doi: 10.18632/oncotarget.15863.

5.

Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer.

Gallenne T, Ross KN, Visser NL, Salony, Desmet CJ, Wittner BS, Wessels LFA, Ramaswamy S, Peeper DS.

Oncotarget. 2017 Mar 15;8(13):20572-20587. doi: 10.18632/oncotarget.16244.

6.

p53 gain-of-function mutations promote metastasis via ENTPD5 upregulation and enhanced N-glycoprotein folding.

Timofeev O, Stiewe T.

Mol Cell Oncol. 2017 Feb 3;4(2):e1288678. doi: 10.1080/23723556.2017.1288678. eCollection 2017.

PMID:
28401189
7.

Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasis.

Xie HY, Shao ZM, Li DQ.

Chin J Cancer. 2017 Mar 29;36(1):36. doi: 10.1186/s40880-017-0202-y. Review.

8.

The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants.

Miller M, Shirole N, Tian R, Pal D, Sordella R.

J Cancer Biol Res. 2016;4(4). pii: 1091. Epub 2016 Dec 23.

9.

Glucocorticoid receptor signalling activates YAP in breast cancer.

Sorrentino G, Ruggeri N, Zannini A, Ingallina E, Bertolio R, Marotta C, Neri C, Cappuzzello E, Forcato M, Rosato A, Mano M, Bicciato S, Del Sal G.

Nat Commun. 2017 Jan 19;8:14073. doi: 10.1038/ncomms14073.

10.

STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.

Otaka Y, Rokudai S, Kaira K, Fujieda M, Horikoshi I, Iwakawa-Kawabata R, Yoshiyama S, Yokobori T, Ohtaki Y, Shimizu K, Oyama T, Tamura J, Prives C, Nishiyama M.

Clin Cancer Res. 2017 Jul 1;23(13):3442-3452. doi: 10.1158/1078-0432.CCR-16-1815. Epub 2017 Jan 13.

PMID:
28087642
11.

Comprehensive phenotypic analysis of knockout mice deficient in cyclin G1 and cyclin G2.

Ohno S, Ikeda JI, Naito Y, Okuzaki D, Sasakura T, Fukushima K, Nishikawa Y, Ota K, Kato Y, Wang M, Torigata K, Kasama T, Uchihashi T, Miura D, Yabuta N, Morii E, Nojima H.

Sci Rep. 2016 Dec 16;6:39091. doi: 10.1038/srep39091.

12.

Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.

Vogiatzi F, Brandt DT, Schneikert J, Fuchs J, Grikscheit K, Wanzel M, Pavlakis E, Charles JP, Timofeev O, Nist A, Mernberger M, Kantelhardt EJ, Siebolts U, Bartel F, Jacob R, Rath A, Moll R, Grosse R, Stiewe T.

Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8433-E8442. doi: 10.1073/pnas.1612711114. Epub 2016 Dec 12.

13.

The Regulation of Tumor Suppressor p63 by the Ubiquitin-Proteasome System.

Armstrong SR, Wu H, Wang B, Abuetabh Y, Sergi C, Leng RP.

Int J Mol Sci. 2016 Dec 6;17(12). pii: E2041. Review.

14.

The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.

Xiong S, Pant V, Zhang Y, Aryal NK, You MJ, Kusewitt D, Lozano G.

J Pathol. 2017 Mar;241(4):501-510. doi: 10.1002/path.4854. Epub 2017 Jan 6.

PMID:
27925213
15.

ΔNp63α and microRNAs: leveraging the epithelial-mesenchymal transition.

Stacy AJ, Craig MP, Sakaram S, Kadakia M.

Oncotarget. 2017 Jan 10;8(2):2114-2129. doi: 10.18632/oncotarget.13797.

16.
17.

Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness.

Olivos DJ, Mayo LD.

Int J Mol Sci. 2016 Nov 26;17(12). pii: E1982. Review.

18.

TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway.

Su X, Napoli M, Abbas HA, Venkatanarayan A, Bui NHB, Coarfa C, Gi YJ, Kittrell F, Gunaratne PH, Medina D, Rosen JM, Behbod F, Flores ER.

Oncogene. 2017 Apr 27;36(17):2377-2393. doi: 10.1038/onc.2016.388. Epub 2016 Nov 21.

19.
20.

ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.

Li D, Marchenko ND.

Oncotarget. 2017 Jan 24;8(4):5823-5833. doi: 10.18632/oncotarget.12878.

Supplemental Content

Support Center